BIO-TECHNE CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.96 USD | -0.40% |
|
-6.88% | -19.47% |
| Apr. 18 | Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85 | MT |
| Apr. 08 | RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Bio-Techne Earnin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows:
- biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc.
Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Calendar
2024-05-01
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
62.21
USD
Average target price
80.43
USD
Spread / Average Target
+29.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.47% | 9.78B | |
| -2.15% | 41.35B | |
| +42.15% | 40.38B | |
| +1.47% | 39.05B | |
| -14.19% | 26.67B | |
| +1.61% | 24.07B | |
| -24.81% | 18.36B | |
| -4.08% | 11.68B | |
| +20.49% | 11.6B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Transcript : Bio-Techne Corporation, Q4 2022 Earnings Call, Aug 04, 2022
